We are Sorry, This Page doesn't Exist
Gilead signs remdesivir licensing deals with Mylan, four other manufacturers
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Gilead announces non-U.S. deals with five generic drugmakers for remdesivir
Shares of Gilead Sciences Inc. were down 1.2% in trading on Tuesday after the drugmaker listed on its website five generic drugmakers that will pr.....»»
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
Zacks.....»»
Gilead Reports Q1 Earnings Beat, Anticipates Short-Term Impact From Coronavirus
Gilead Sciences (NASDAQ: GILD) reported quarterly earnings of $1.68 per share on Thursday, which beat the analyst consensus estimate of $1.57 by 7.01%. This is a 4.55% decrease over earnings of $1.76 per share from the same period last year. read more.....»»
Baird Analyst Says "Don"t Give Up" Yet On Gilead"s Remdesivir
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) fell Thursday afternoon in reaction to a disappointing report on an early readout for its remdesivir therapy, but investors should not "give up on this Latest Ratings fo.....»»
Gilead Analyst Sees Catalyst Ahead In Data Readout For Potential Coronavirus Treatment
Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir is one of the frontrunners among investigational drugs to treat COVID-19. Latest.....»»
Analyst Says Gilead"s Remdesivir Could Be Approved "Within Months" For COVID-19 Treatment
A senior research analyst at Piper Sandler believes Gilead Sciences Inc.'s (NASDAQ: GILD) Remdesivir antiviral may soon be approved for COVID-19 treatm.....»»
The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences
Zacks.....»»
Roche and Gilead Losing Patent Protection on Top Sellers
Seven pharma companies face generic competition for medications that generated high U.S. sales in 2018Related Stocks: RHHBY, GILD, PFE, AMGN, GSK, INDV,.....»»
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
Zacks.....»»
Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes
Gilead Sciences, Inc. (NASDAQ: GILD) reported after the market close Thursday with results.....»»
Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes
Gilead Sciences, Inc. (NASDAQ: GILD) reported after the market close Thursday with results that left investors uninspired. The Analysts Morgan Stanley analyst Matthew.....»»
The Zacks Analyst Blog Highlights: Cisco Systems, SAP, Gilead Sciences, Bank of America and Caterpillar
Zacks.....»»
DURECT Soars On Out-Licensing Deal With Gilead For Up To $170M
Penny stock DURECT Corporation (NASDAQ: DRRX) is advancing strongly Monday following an out-licensing deal with Gilead Sciences, Inc. (NASDAQ: GILD). read more.....»»
UBS Upgrades Gilead, Sees EPS Upside In 2019
It’s been a rough couple of years for Gilead Sciences, Inc. (NASDAQ: GILD) investors, with the stock down more than 30 percent since early 2016. One analyst said Wednesday that Gilead may finally be turning the corner this year. Latest Ratin.....»»